Holen Sie sich die Stockscreener-App
6.60
0.76%
0.05
Schlusskurs vom Vortag:
$6.55
Offen:
$6.55
24-Stunden-Volumen:
660.04K
Relative Volume:
0.45
Marktkapitalisierung:
$498.63M
Einnahmen:
$11.40B
Nettoeinkommen (Verlust:
$-95.73M
KGV:
-2.6939
EPS:
-2.45
Netto-Cashflow:
$-64.37M
1W Leistung:
+7.32%
1M Leistung:
+20.88%
6M Leistung:
-14.95%
1J Leistung:
-23.70%
1-Tages-Spanne:
$6.5123
$6.74
1-Wochen-Bereich:
$6.16
$6.74
52-Wochen-Spanne:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
Firmenname
Mind Medicine Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MNMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.60 | 464.65M | 11.40B | -95.73M | -64.37M | -2.45 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Mind Medicine Inc Aktie (MNMD) Neueste Nachrichten
Was Jim Cramer Right About Mind Medicine (MNMD) Stock? - Insider Monkey
(MNMD) Technical Data - news.stocktradersdaily.com
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? - MSN
MindMed to Present at the 2025 RBC Capital Markets Global Health - GuruFocus
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Joplin Globe
MindMed projects 2026 trial readouts for pivotal MM120 studies in GAD and MDD - MSN
MindMed to Host Key Opinion Leader Webinar on Substance Use Diso - GuruFocus
Mind Medicine (MNMD) Rating and Price Target Maintained by Chard - GuruFocus
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance - insights.citeline.com
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... - Yahoo Finance
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... By GuruFocus - Investing.com Canada
MindMed Advances Phase 3 Trials for Brain Health - TipRanks
Transcript : Mind Medicine Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
MindMed Advances Phase 3 Trials for Brain Health Treatments - TipRanks
MindMed Q1 2025 slides: Phase 3 trials advance as cash position remains strong - Investing.com Australia
Earnings call transcript: MindMed Q1 2025 results show mixed signals By Investing.com - Investing.com Australia
Earnings call transcript: MindMed Q1 2025 results show mixed signals - Investing.com
MindMed (MNMD) Advances Phase 3 Trials with Growing Enthusiasm | - GuruFocus
Mind Medicine (MindMed) Inc. SEC 10-Q Report - TradingView
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates - Business Wire
(MNMD) Long Term Investment Analysis - news.stocktradersdaily.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 | MNMD Stock News - GuruFocus
Great week for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) institutional investors after losing 28% over the previous year - simplywall.st
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Yahoo Finance
Mind Medicine (Mindmed) IncMindmed Enters Into First Amendment To Loan And Security AgreementSEC Filing - marketscreener.com
MindMed Announces New Employee Inducement Grants | MNMD Stock Ne - GuruFocus
MindMed Announces New Employee Inducement Grants | MNMD Stock News - GuruFocus
MindMed Announces New Employee Inducement Grants - Business Wire
Lobbying Update: $100,000 of MIND MEDICINE (MINDMED) INC. lobbying was just disclosed - Nasdaq
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
How the (MNMD) price action is used to our Advantage - news.stocktradersdaily.com
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
Finanzdaten der Mind Medicine Inc-Aktie (MNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):